GSK, iTeos lung cancer therapy outperforms Jemperli in mid-stage trial
https://seekingalpha.com/news/4149777-gsk-iteos-lung-cancer-drug-outperforms-jemperli?source=feed_sector_healthcare
Sep 14, 2024 - iTeos (ITOS) stock is in focus as experimental cancer doublet therapy, developed with GSK, outperformed Jemperliin a mid-stage trial for lung cancer. Read more here.
0
Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More
https://www.zacks.com/stock/news/2335461/biotech-stock-roundup-tern-smmt-stocks-surge-on-study-data-gsk-s-vaccine-study-fails-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2335461
Sep 12, 2024 - Terns Pharmaceuticals and Summit Therapeutics are in the spotlight following positive updates on key candidates.
0
Moderna shares plunge on plans to cut $1.1 billion in costs, launch 10 new products by 2027
https://www.cnbc.com/2024/09/12/moderna-rd-day-1-billion-in-cost-cuts-10-product-launches-planned.html
Sep 12, 2024 - Moderna is deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.
0
GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal
https://www.zacks.com/stock/news/2335368/gsk-s-hsv-vaccine-study-fails-to-meet-primary-efficacy-goal?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2335368
Sep 12, 2024 - The phase I/II proof-of-concept study evaluating GSK's herpes simplex virus vaccine candidate, GSK3943104, fails to meet the primary efficacy objective.
0
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
https://www.zacks.com/stock/news/2332724/are-you-a-value-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2332724
Sep 06, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
0
GSK’s Nucala succeeds in late-stage study for lung disorder, COPD
https://seekingalpha.com/news/4147607-gsk-nucala-succeeds-in-copd-trial?source=feed_sector_healthcare
Sep 06, 2024 - GSK's (GSK) asthma therapy Nucala reaches main goal in a Phase 3 trial for COPD, demonstrating significant reduction in exacerbations. Read more here.
0
Top Stock Reports for Apple, Tesla & NextEra Energy
https://www.zacks.com/commentary/2331983/top-stock-reports-for-apple-tesla-nextera-energy?cid=CS-ZC-FT-research_daily-2331983
Sep 05, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Tesla, Inc. (TSLA) and NextEra Energy, Inc. (NEE), as well as two micro-cap stocks Investors Title Company (ITIC) and Autoscope Technologies Corporation (AATC).
0
GSK's RSV Vaccine Arexvy Gets EU Nod for Adults Aged 50-59 Years
https://www.zacks.com/stock/news/2329179/gsk-s-rsv-vaccine-arexvy-gets-eu-nod-for-adults-aged-50-59-years?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2329179
Aug 29, 2024 - The European Commission approves GSK's RSV vaccine, Arexvy, for use in adults aged 50-59 years with increased risk of the disease.
0
GSK Stock Gains 18.5% Year to Date: Time to Buy, Sell or Hold?
https://www.zacks.com/stock/news/2328811/gsk-stock-gains-18-5-year-to-date-time-to-buy-sell-or-hold?cid=CS-ZC-FT-analyst_blog|rank_focused-2328811
Aug 29, 2024 - GSK's cheap valuation, reasonable stock price appreciation and bright growth potential indicate that investors should stay invested.
0
GSK stock climbs on Delaware court ruling in Zantac case
https://seekingalpha.com/news/4144294-gsk-stock-climbs-on-delaware-court-ruling-in-zantac-case?source=feed_sector_healthcare
Aug 27, 2024 - GSK (GSK) stock was up 3% Tuesday following a Delaware court ruling on whether certain evidence should be allowed in an ongoing case over the safety of its recalled drug Zantac.
0